Biology Reference
In-Depth Information
Kadoshima-Yamaoka K, Goto M, Murakawa M, Yoshioka R, Tanaka Y, Inoue H, Murafuji H,
Kanki S, Hayashi Y, Nagahira K, Ogata A, Nakatsuka T, Fukuda Y (2009a) ASB16165,
a phosphodiesterase 7A inhibitor, reduces cutaneous TNF
a
level and ameliorates skin edema
in phorbol ester 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation model in
mice. Eur J Pharmacol 613:163-166
Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, Hayashi Y,
Nagahira K, Miura K, Nakatsuka T, Chamoto K, Fukuda Y, Nishimura T (2009b) Effect of
phosphodiesterase 7 inhibitor ASB16165 on development and function of cytotoxic T
lymphocyte. Int Immunopharmacol 9:97-102
Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, Nagahira A,
Hayashi Y, Nagahira K, Miura K, Nakatsuka T, Chamoto K, Fukuda Y, Nishimura T (2009c)
ASB16165, a novel inhibitor for phosphodiesterase 7A (PDE7A), suppresses IL-12-induced
IFN-gamma production by mouse activated T lymphocytes. Immunol Lett 122:193-197
Kalkhoven E, Wissink S, van der Saag PT, van der Burg B (1996) Negative interaction
between the RelA(p65) subunit of NF-
k
B and the progesterone receptor. J Biol Chem 271:
6217-6224
Kaur M, Chivers JE, Giembycz MA, Newton R (2008a) Long-acting
b
2
-adrenoceptor agonists
synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and
smooth muscle cells. Mol Pharmacol 73:201-214
Kaur M, Holden NS, Wilson SM, Sukkar MB, Chung KF, Barnes PJ, Newton R, Giembycz MA
(2008b) Effect of
b
2
-adrenoceptor agonists and other cAMP-elevating agents on inflammatory
gene expression in human ASM cells: a role for protein kinase A. Am J Physiol Lung Cell Mol
Physiol 295:L505-L514
Kim J, Jia L, Stallcup MR, Coetzee GA (2005) The role of protein kinase A pathway and cAMP
responsive element-binding protein in androgen receptor-mediated transcription at the pros-
tate-specific antigen locus. J Mol Endocrinol 34:107-118
King EM, Holden NS, Gong W, Rider CF, Newton R (2009) Inhibition of NF-
k
B-dependent
transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38
MAPK. J Biol Chem 284:26803-26815
Kita T, Fujimura M, Myou S, Watanabe K, Waseda Y, Nakao S (2009) Effects of KF19514,
a phosphodiesterase 4 and 1 inhibitor, on bronchial inflammation and remodeling in a murine
model of chronic asthma. Allergol Int 58:267-275
Kvien TK, Fjeld E, Slatkowsky-Christensen B, Nichols M, Zhang Y, Proven A, Mikkelsen K,
Palm O, Borisy AA, Lessem J (2008) Efficacy and safety of a novel synergistic drug candidate,
CRx-102, in hand osteoarthritis. Ann Rheum Dis 67:942-948
Lazaar AL, Panettieri RA (2003) Is airway remodeling clinically relevant in asthma? Am J Med
115:652-659
Leeman M, Lejeune P, Melot C, Naeije R (1987) Reduction in pulmonary hypertension and
in airway resistances by enoximone (MDL 17, 043) in decompensated COPD. Chest 91:
662-666
Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, Semigran MJ (2005)
Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary
hypertension: combined administration with inhaled nitric oxide. Chest 127:1647-1653
Lim S, Jatakanon A, Gordon D, MacDonald C, Chung KF, Barnes PJ (2000) Comparison of high
dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose
inhaled steroids alone in chronic asthma in general practice. Thorax 55:837-841
MacDonald D, Perrier H, Liu S, Laliberte F, Rasori R, Robichaud A, Masson P, Huang Z (2000)
Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity
probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ). J Med
Chem 43:3820-3823
Madden BP, Allenby M, Loke TK, Sheth A (2006) A potential role for sildenafil in the manage-
ment of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol
44:372-376
